Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 3, 2015, Pages 348-354

  May, Margaret T ^a   Justice, Amy C ^b,c   Birnie, Kate ^a   Ingle, Suzanne M ^a   Smit, Colette ^d   Smith, Colette ^e   Neau, Didier ^f   Guiguet, Marguerite ^g   Schwarze Zander, Carolynne ^h   Moreno, Santiago ⁱ   Guest, Jodie L ^j   Monforte, Antonella D'Arminio ^k   Tural, Cristina ^l   Gill, Michael J ^m   Bregenzer, Andrea ⁿ   Kirk, Ole ^o   Saag, Michael ^p   Sterling, Timothy R ^q   Crane, Heidi M ^r   Sterne, Jonathan A C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d STICHTING HIV MONITORING   (Netherlands)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f HÔPITAL PELLEGRIN   (France)

^g INSERM   (France)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j ATLANTA VA MEDICAL CENTER   (United States)

^k UNIVERSITY OF MILAN   (Italy)

^l HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

^p University of Alabama at Birmingham   (United States)

^q VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

antiretroviral therapy; cohort study; hepatitis C virus; HIV 1; injection drug use; mortality

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT DURATION; VIRUS ATTENUATION; COMPLICATION; HIV INFECTIONS; MIDDLE AGED; SUBSTANCE ABUSE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84933045407     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000603     Document Type: Article

References (35)

1. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
2. Larsen MV, Omland LH, Gerstoft J, et al. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide populationbased cohort study. Addiction. 2010;105:529-535.
3. Mathers BM, Degenhardt L, Bucello C, et al. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91:102-123.
4. Gill MJ, May MT, Lewden C, et al. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohorts. Clin Infect Dis. 2010;50:1387-1396.
5. Green TC, McGowan SK, Yokell MA, et al. HIV infection and risk of overdose: a systematic review and meta-analysis. AIDS. 2012;26:403-417.
6. Ferreros I, Lumbreras B, Hurtado I, et al. The shifting pattern of causespecific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction. 2008;103:651-659.
7. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262-270.
8. Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIVinfected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;41:864-872.
9. Schiavini M, Angeli E, Mainini A, et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med. 2006;7:331-337.
10. Izzedine H, Sene D, Cacoub P, et al. Kidney diseases in HIV/HCV-coinfected patients. AIDS. 2009;23:1219-1226.
11. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367-387.
12. Vickerman P, Hickman M, May M, et al. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? an ecological analysis. Addiction. 2010;105:311-318.
13. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-583.
14. Soriano V, Labarga P, Fernandez-Montero JV, et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antiviral Res. 2013;97:36-40.
15. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368: 45-53.
16. Murray M, Hogg RS, Lima VD, et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med. 2012;13:89-97.
17. May MT, Ingle SM, Costagliola D, et al. Cohort profile: antiretroviral therapy cohort collaboration (ART-CC). Int J Epidemiol. 2014;43:691-702.
18. Green TC, Kershaw T, Lin HQ, et al. Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend. 2010;110:208-220.
19. Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55:1408-1416.
20. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469-477.
21. Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology. 2009;50:393-399.
22. Butt AA, Justice AC, Skanderson M, et al. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-389.
23. Butt AA, McGinnis KA, Skanderson M, et al. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2010;30:240-250.
24. Piasecki BA, Lewis JD, Reddy KR, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology. 2004;40:892-899.
25. Grebely J, Raffa JD, Lai C, et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol. 2007;21:447-451.
26. Schnuriger A, Dominguez S, Guiguet M, et al. Acute hepatitis C in HIVinfected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS. 2009;23: 2079-2089.
27. Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 2006;3:e492.
28. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liverrelated mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012; 57:743-751.
29. Fischer MJ, Wyatt CM, Gordon K, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr. 2010;53:222-226.
30. Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49:225-232.
31. Butt AA, Fultz SL, Kwoh CK, et al. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology. 2004;40:115-119.
32. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
33. Edelman E, Gordon K, Glover K, et al. The next therapeutic challenge in HIV: Polypharmacy. Drugs Aging. 2013;30:16.
34. Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust. 2012;196:629-632.
35. Martin N, Vickerman P, Grebely J, et al. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58:1598-1609.